Third largest pharmaceuticals market by 2020 in terms of incremental growth.
20% of global exports in generics, making it the largest provider of generic medicines globally.
USD 45 Billion in revenue by 2020, revenue of USD 55 billion by 2020 as base case, and can grow to USD 70 billion in a aggressive case scenario.
USD 26.1 Billion in generics by 2016.
USD 200 Billion to be spent on infrastructure by 2024.
India's filing of Drug Master Files's (DMF's) with USFDA as of Dec 2013 is 3411, the highest filed by any country in the world.
Total exports of Drugs, Pharmaceuticals for 2013-14 at USD 15,095 million, recording a growth rate 2.5% over the corresponding period of previous years.

Reasons To Invest

India is expected to rank amongst the top three pharmaceutical markets in terms of incremental growth by 2020.
India will become the sixth largest market globally in terms of absolute size by zero.
India’s generic drugs account for 20% of global exports in terms of volume, making the country the largest provider of generic medicines globally.
India’s cost of production is significantly lower than that of the USA and almost half of that of Europe.
A skilled workforce as well as high managerial and technical competence.
Economic prosperity is likely to improve affordability for generic drugs in the market.
Approval time for new facilities has been drastically reduced.

Statistics

The country’s pharmaceuticals industry is expected to account for about 3.1-3.6% of the global pharma industry by value and currently accounts for 10% by volume, by 2016.
Industry revenues are expected to expand at a CAGR of 12.1% during 2012-20 and reach USD 45 Billion.
The healthcare sector in India is expected to grow to USD 250 Billion by 2020 from USD 65 Billion currently.
The generics market is expected to grow to USD 26.1 Billion by 2016 from USD 11.3 Billion in 2011.

Growth Drivers

Between 2011 and 2016, patent drugs worth USD 255 Billion are estimated to go off-patent leading to a huge surge in generic product and tremendous opportunities for companies.
By 2020, it will grow to USD 11 billion - a CAGR of 18%, with the potential to reach USD 13 billion - at an aggresive CAGR of 20%.
With increasing penetration of chemists, especially in rural India, OTC drugs will be readily available.
Pharma companies have increased spending to tap rural markets and develop better infrastructure. The market share of hospitals is expected to increase from 13.1% in 2009 to 26% in 2020.
Following the introduction of product patents, several multinational companies are expected to launch patented drugs in India.
The purported rise of lifestyle diseases in India is expected to boost industry sales figures.
Over USD 200 Billion is to be spent on medical infrastructure in the next decade.
Rising levels of education are set to increase the acceptability of pharmaceuticals.
India’s patient pool is expected to increase to over 20% in the next 10 years, mainly due to the rise in population.